Cell Source Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2017
2018
Cash & Short Term Investments
18.70
19.50
6.90
371.00
18.90
Other Current Assets
-
101.50
206.60
160.60
46.90
Total Current Assets
18.70
121.00
213.60
531.70
65.80
Net Property, Plant & Equipment
-
2.10
1.30
-
-
Other Assets
-
-
152.90
-
-
Total Assets
18.70
123.10
367.80
531.70
65.80
ST Debt & Current Portion LT Debt
1.10
100.00
1,644.20
2,321.10
Accounts Payable
-
285.40
-
201.80
Other Current Liabilities
6.20
3,521.40
4,405.40
2,566.10
Total Current Liabilities
7.30
3,906.80
6,049.60
5,089.10
Long-Term Debt
-
-
72.00
-
Other Liabilities
-
-
4.50
-
Total Liabilities
7.30
3,906.80
6,126.00
5,089.10
Common Equity (Total)
11.30
3,783.70
5,758.20
4,558.00
Total Shareholders' Equity
11.30
3,783.70
5,758.20
4,557.40
Total Equity
11.30
3,783.70
5,758.20
4,557.40
Liabilities & Shareholders' Equity
18.70
123.10
367.80
531.70
Preferred Stock (Carrying Value)
-
-
-
0.60

About Cell Source

View Profile
Address
57 West 57th Street
New York New York 10019
United States
Employees -
Website http://www.cell-source.com
Updated 07/08/2019
Cell Source, Inc. is a biotechnology company, which engages in the development of cell therapy treatments. It operates through Veto-Cell technology, which represents immune system management. The company was founded on June 6, 2012 and is headquartered in New York, NY.